Suppr超能文献

玻璃体内注射阿柏西普治疗风疹性视网膜病变相关脉络膜新生血管化

Intravitreal aflibercept for the treatment of choroidal neovascularization associated with rubella retinopathy.

作者信息

Kiziltoprak Hasan, Yetkin Esat, Tekin Kemal, Koc Mustafa, Akalin İrfan, Teke Mehmet Yasin

机构信息

Ulucanlar Eye Training and Research Hospital, 06240, Ankara, Turkey.

Kars State Hospital, Kars, Turkey.

出版信息

Int Ophthalmol. 2019 Feb;39(2):477-484. doi: 10.1007/s10792-018-0830-5. Epub 2018 Feb 6.

Abstract

PURPOSE

To report a case of choroidal neovascularization (CNV) associated with rubella retinopathy (RR) treated with intravitreal aflibercept.

CASE PRESENTATION

A 15-year-old girl presented a complaint of visual decrease in her left eye. She had a history of hearing decrease since she was 1 year old in addition to patent ductus arteriosus. On ocular examination, the best corrected visual acuity (BCVA) was 20/20 in the right eye and 20/400 in the left eye. Dilated fundus examinations revealed a classic salt-and-pepper appearance in both eyes and a whitish subretinal lesion with retinal hemorrhages in the left macula. Fundus fluorescein angiography (FFA) of the left eye illustrated a pattern of diffuse spotty fluorescence with an active subfoveal CNV lesion, that hyperfluoresces in the early phases of the FFA, maintains well-demarcated borders, and leaks. Spectral domain optical coherence tomography (SD-OCT) revealed thickened and elevated retinal layers at the macula due to the subretinal and intraretinal fluid with foveal and extrafoveal protruding hyper-reflective lesion in the left eye. Single dose of intravitreal aflibercept was performed to the left eye and at the first month after the injection, the BCVA improved to 20/100 and the OCT revealed scar formation. At the follow-up visits, the macula was similar to those at the first month post-injection, and the BCVA was preserved. No additional injections were needed.

CONCLUSION

Intravitreal aflibercept may be a treatment alternative, which provides satisfactory anatomical and functional results and leads to a better visual acuity in cases with RR complicated by CNV.

摘要

目的

报告1例玻璃体内注射阿柏西普治疗风疹性视网膜病变(RR)相关脉络膜新生血管(CNV)的病例。

病例介绍

一名15岁女孩主诉左眼视力下降。她自1岁起除患有动脉导管未闭外,还有听力下降病史。眼部检查显示,右眼最佳矫正视力(BCVA)为20/20,左眼为20/400。散瞳眼底检查发现双眼均有典型的椒盐样外观,左眼黄斑区有白色视网膜下病变伴视网膜出血。左眼眼底荧光血管造影(FFA)显示为弥漫性斑点状荧光模式,伴有活动性黄斑下CNV病变,在FFA早期呈高荧光,边界清晰,有渗漏。频域光学相干断层扫描(SD-OCT)显示左眼黄斑区视网膜层因视网膜下和视网膜内液体积聚而增厚和隆起,伴有黄斑和黄斑外突出的高反射病变。对左眼进行了单剂量玻璃体内注射阿柏西普,注射后第一个月,BCVA提高到20/100,OCT显示有瘢痕形成。在随访中,黄斑情况与注射后第一个月相似,BCVA得以维持。无需额外注射。

结论

玻璃体内注射阿柏西普可能是一种治疗选择,对于RR合并CNV的病例,它能提供令人满意的解剖和功能结果,并带来更好的视力。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验